CLINICAL_TRIALS
trial_result
· 2010-05-20
Clinical Trial Update: Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder [Phase 2]
Summary
Phase 2 trial assessing the efficacy, safety, and tolerability of XBD173 in patients with generalized anxiety disorder. The study status is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Anxiety Disorders | Phase 2 | Status: COMPLETED